205 related articles for article (PubMed ID: 37388717)
1. Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause.
Conklin M; Santoro N
Ther Adv Reprod Health; 2023; 17():26334941231177611. PubMed ID: 37388717
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.
Umland EM; Falconieri L
Int J Womens Health; 2012; 4():305-19. PubMed ID: 22870045
[TBL] [Abstract][Full Text] [Related]
3. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H; Lademacher C; Siddiqui E; Fraser GL
Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
[No Abstract] [Full Text] [Related]
4. Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
DePree B
touchREV Endocrinol; 2023 Nov; 19(2):69-72. PubMed ID: 38187079
[TBL] [Abstract][Full Text] [Related]
5. Menopause review: Emerging treatments for menopausal symptoms.
Patel B; S Dhillo W
Best Pract Res Clin Obstet Gynaecol; 2022 May; 81():134-144. PubMed ID: 34965909
[TBL] [Abstract][Full Text] [Related]
6. A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
Javernick JA
Nurs Womens Health; 2024 Feb; 28(1):80-84. PubMed ID: 38161058
[TBL] [Abstract][Full Text] [Related]
7. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.
Menopause; 2015 Nov; 22(11):1155-72; quiz 1173-4. PubMed ID: 26382310
[TBL] [Abstract][Full Text] [Related]
8. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms.
Sassarini J; Anderson RA
Expert Opin Investig Drugs; 2024 Jan; 33(1):19-26. PubMed ID: 38224099
[TBL] [Abstract][Full Text] [Related]
9. Critical appraisal of paroxetine for the treatment of vasomotor symptoms.
Carroll DG; Lisenby KM; Carter TL
Int J Womens Health; 2015; 7():615-24. PubMed ID: 26124682
[TBL] [Abstract][Full Text] [Related]
10. Duration of menopausal vasomotor symptoms over the menopause transition.
Avis NE; Crawford SL; Greendale G; Bromberger JT; Everson-Rose SA; Gold EB; Hess R; Joffe H; Kravitz HM; Tepper PG; Thurston RC;
JAMA Intern Med; 2015 Apr; 175(4):531-9. PubMed ID: 25686030
[TBL] [Abstract][Full Text] [Related]
11. Insights into the genetics of menopausal vasomotor symptoms: genome-wide analyses of routinely-collected primary care health records.
Ruth KS; Beaumont RN; Locke JM; Tyrrell J; Crandall CJ; Hawkes G; Frayling TM; Prague JK; Patel KA; Wood AR; Weedon MN; Murray A
BMC Med Genomics; 2023 Oct; 16(1):231. PubMed ID: 37784116
[TBL] [Abstract][Full Text] [Related]
12. The role of kisspeptin/neurokinin B/dynorphin neurons in pathomechanism of vasomotor symptoms in postmenopausal women: from physiology to potential therapeutic applications.
Szeliga A; Czyzyk A; Podfigurna A; Genazzani AR; Genazzani AD; Meczekalski B
Gynecol Endocrinol; 2018 Nov; 34(11):913-919. PubMed ID: 29902942
[TBL] [Abstract][Full Text] [Related]
13. Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI).
Thurston RC; Carroll JE; Levine M; Chang Y; Crandall C; Manson JE; Pal L; Hou L; Shadyab AH; Horvath S
J Clin Endocrinol Metab; 2020 Apr; 105(4):1221-7. PubMed ID: 32080740
[TBL] [Abstract][Full Text] [Related]
14. "Veozah (Fezolinetant): A Promising Non-Hormonal Treatment for Vasomotor Symptoms in Menopause".
Shaukat A; Mujeeb A; Shahnoor S; Nasser N; Khan AM
Health Sci Rep; 2023 Oct; 6(10):e1610. PubMed ID: 37808928
[TBL] [Abstract][Full Text] [Related]
15. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages.
Deecher DC; Dorries K
Arch Womens Ment Health; 2007; 10(6):247-57. PubMed ID: 18074100
[TBL] [Abstract][Full Text] [Related]
16. Nonhormone therapies for vasomotor symptom management.
Iyer TK; Fiffick AN; Batur P
Cleve Clin J Med; 2024 Apr; 91(4):237-244. PubMed ID: 38561208
[TBL] [Abstract][Full Text] [Related]
17. Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause.
Roberts MZ; Andrus MR
Expert Opin Pharmacother; 2024 Jul; ():. PubMed ID: 38953697
[TBL] [Abstract][Full Text] [Related]
18. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
[TBL] [Abstract][Full Text] [Related]
19. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S; Ottery FD; Cano A; Santoro N; Shapiro M; Stute P; Thurston RC; English M; Franklin C; Lee M; Neal-Perry G
Lancet; 2023 Apr; 401(10382):1091-1102. PubMed ID: 36924778
[TBL] [Abstract][Full Text] [Related]
20. Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Alexander IM; Moore A
J Am Acad Nurse Pract; 2007 Mar; 19(3):152-63. PubMed ID: 17341283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
